Search results
Emend is an antiemetic, a medicine that prevents nausea (feeling sick) and vomiting. Emend is used in patients aged from 6 months to prevent nausea and vomiting caused by chemotherapy (medicines used to treat cancer).
Marketing and manufacturing authorisation holders should report any falsified centrally authorised medicine to the European Medicines Agency (EMA), including a suspected falsified medicine, following the instructions provided.
W dwóch badaniach z udziałem pacjentów otrzymujących chemioterapię z zastosowaniem cisplatyny 68% (352 z 520) pacjentów przyjmujących lek Emend nie miało nudności i wymiotów w okresie 5 dni, w porównaniu z 48% (250 z 523) pacjentów, którzy nie przyjmowali leku.
12 lut 2013 · EMEND® (aprepitant) is an anti-emetic drug indicated for the prevention of nausea and vomiting associated with acute and delayed highly emetogenic cancer chemotherapy including cisplatin, and with moderately emetogenic chemotherapy.Annual monitoring of the conditions of use of this drug has been requested to MSD France laboratory by the ...
This decentralised procedure concerns a generic application claiming essential similarity with the innovator product Emend 80 mg and 125 mg hard capsules(EU/1/03/262) which has been registered in the EEA by Merck Sharp & Dohme Ltd, UK since 11 November 2003 (original product). 125 mg + 80. mg .
Europejska Agencja Leków (EMA) 22 lutego 2013 roku zatwierdziła zmienioną Charakterystykę Produktu Leczczniedgo Emend.
How to use the defective product report to notify a quality defect to European Medicines Agency. You should receive an acknowledgement in four hours during EMA business hours. If you do not, you can phone EMA on: Tel. +31 (0)88 781 6000 (EMA switchboard) Tel. +31 (0)88 781 7676.
